Assessing the Risk of Antimicrobial Resistance

About this episode

This episode explores the urgent health challenge of Antimicrobial Resistance and its implications for health systems and the economy.

Antimicrobial Resistance (AMR) is one of the most urgent health challenges today, making infections harder—and sometimes impossible—to treat. This episode of Fixed on ESG explores what AMR is, why it matters, and its wide-ranging impact on health systems and the global economy. We also highlight the science behind resistance, why innovation in diagnostics, vaccines, and stewardship is critical, and what investors should consider as AMR drives rising healthcare costs, regulatory pressures, and opportunities in new technologies. PGIM's Birgit Lundem Jakobsen, ESG Specialist, hosts this discussion with Amish Acharya, Senior Scientific and Clinical Advisor from the Fleming Initiative. Recorded on January 20, 2026.

People in this episode

Host: Birgit Lundem Jakobsen

Guest: Amish Acharya

Topics covered

• Antimicrobial Resistance
• health systems
• global economy
• innovation in diagnostics
• vaccines
• healthcare costs
• regulatory pressures

Keywords

• AMR
• healthcare
• infections
• diagnostics
• vaccines
• investors
• technology

Mentioned in this episode

Organizations: Fleming Initiative, PGIM

Books & works: Antimicrobial Resistance (AMR)

More episodes of Fixed on ESG

• COP30: Key Takeaways from the Amazon Summit · December 23, 2025 · 27 min
• Propelling Equitable Access to Medicine · November 20, 2025 · 25 min
• Running a Tight Ship: IMO's Net-Zero Regulations · September 23, 2025 · 16 min
• EU ESG Regulation: Players, Policy, and Purpose · September 9, 2025 · 28 min
• The Insurance Industry in the Climate Conversation · July 30, 2025 · 29 min
• Behind the Seams: Unraveling Fast Fashion's ESG Challenges · June 24, 2025 · 20 min